Onco-Innovations Launches Preclinical Development of PNKP Inhibitor with Validated Analytical Methods by Nucro-Technics

Reuters2025-09-29

Onco-Innovations Launches Preclinical Development of PNKP Inhibitor with Validated Analytical Methods by Nucro-Technics

Onco-Innovations Ltd. has announced the initiation of preclinical and analytical development for its proprietary Polynucleotide Kinase Phosphatase (PNKP) inhibitor technology. In collaboration with Nucro-Technics Inc., the company has begun laboratory work to develop and validate advanced analytical methods, using liquid chromatography-mass spectrometry (LC-MS), to measure the PNKP inhibitor in preclinical samples and drug formulations. These methods are essential for regulatory submissions and will underpin future studies, including formal toxicology and pharmacokinetics assessments. The results represent a key step in Onco-Innovations' IND-enabling program and have not yet been presented, as the validated methods will serve as the foundation for upcoming research and regulatory filings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1078886) on September 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2571949870?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 12:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571949870","market":"us","top_or_hot":-1,"title":"Onco-Innovations Launches Preclinical Development of PNKP Inhibitor with Validated Analytical Methods by Nucro-Technics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Onco-Innovations Launches Preclinical Development of PNKP Inhibitor with Validated Analytical Methods by Nucro-Technics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Onco-Innovations Ltd. has announced the initiation of preclinical and analytical development for its proprietary Polynucleotide Kinase Phosphatase (PNKP) inhibitor technology. In collaboration with Nucro-Technics Inc., the company has begun laboratory work to develop and validate advanced analytical methods, using liquid chromatography-mass spectrometry (LC-MS), to measure the PNKP inhibitor in preclinical samples and drug formulations. These methods are essential for regulatory submissions and will underpin future studies, including formal toxicology and pharmacokinetics assessments. The results represent a key step in Onco-Innovations' IND-enabling program and have not yet been presented, as the validated methods will serve as the foundation for upcoming research and regulatory filings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1078886) on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Onco-Innovations Launches Preclinical Development of PNKP Inhibitor with Validated Analytical Methods by Nucro-Technics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOnco-Innovations Launches Preclinical Development of PNKP Inhibitor with Validated Analytical Methods by Nucro-Technics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-29 12:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Onco-Innovations Launches Preclinical Development of PNKP Inhibitor with Validated Analytical Methods by Nucro-Technics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Onco-Innovations Ltd. has announced the initiation of preclinical and analytical development for its proprietary Polynucleotide Kinase Phosphatase (PNKP) inhibitor technology. In collaboration with Nucro-Technics Inc., the company has begun laboratory work to develop and validate advanced analytical methods, using liquid chromatography-mass spectrometry (LC-MS), to measure the PNKP inhibitor in preclinical samples and drug formulations. These methods are essential for regulatory submissions and will underpin future studies, including formal toxicology and pharmacokinetics assessments. The results represent a key step in Onco-Innovations' IND-enabling program and have not yet been presented, as the validated methods will serve as the foundation for upcoming research and regulatory filings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1078886) on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0077","symbol_name":"质押式回购","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL8y07fQ:1","article_id":"2571949870","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571949870","pubTimestamp":1759118415,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Onco-Innovations Ltd. has announced the initiation of preclinical and analytical development for its proprietary Polynucleotide Kinase Phosphatase  inhibitor technology. In collaboration with Nucro-Technics Inc., the company has begun laboratory work to develop and validate advanced analytical methods, using liquid chromatography-mass spectrometry , to measure the PNKP inhibitor in preclinical samples and drug formulations. These methods are essential for regulatory submissions and will underpin future studies, including formal toxicology and pharmacokinetics assessments. The results represent a key step in Onco-Innovations' IND-enabling program and have not yet been presented, as the validated methods will serve as the foundation for upcoming research and regulatory filings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informationa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300347":"泰格医药","BK0077":"质押式回购","LU1146622755.USD":"安本中国A股股票基金A Acc","BK0028":"国家队","BK0216":"研究试验","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK0174":"增持"},"translate_title":"Onco-Innovations利用Nucro-Technics经过验证的分析方法启动PNKP抑制剂的临床前开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300347":0.9},"content_text":"Onco-Innovations Launches Preclinical Development of PNKP Inhibitor with Validated Analytical Methods by Nucro-Technics\n    \n\n        Onco-Innovations Ltd. has announced the initiation of preclinical and analytical development for its proprietary Polynucleotide Kinase Phosphatase (PNKP) inhibitor technology. In collaboration with Nucro-Technics Inc., the company has begun laboratory work to develop and validate advanced analytical methods, using liquid chromatography-mass spectrometry (LC-MS), to measure the PNKP inhibitor in preclinical samples and drug formulations. These methods are essential for regulatory submissions and will underpin future studies, including formal toxicology and pharmacokinetics assessments. The results represent a key step in Onco-Innovations' IND-enabling program and have not yet been presented, as the validated methods will serve as the foundation for upcoming research and regulatory filings.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1078886) on September 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2571949870","isCrawlerRequest":true}